SCHEMBL2835378

SCHEMBL2835378

Cc1ccccc1OC(=O)c1c(F)cc(F)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.51
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.42
ATM Q13315 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
SERPINE1 P05121 1/20 0.40
LMNA P02545 3/20 0.40
MEN1 O00255 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
PPARG P37231 1/20 0.39
BCHE P06276 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
PAX8 Q06710 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2838172 0.88 KMT2A (0.52) KMT2AGAAL3MBTL1LMNAMEN1
SCHEMBL2838181 0.87 KMT2A (0.67) KMT2AL3MBTL1ATMTDP1LMNA
SCHEMBL2832842 0.86 KMT2A (0.47) KMT2AL3MBTL1ATMTDP1SLC6A2
SCHEMBL2834909 0.85 KMT2A (0.55) KMT2AGAAL3MBTL1TDP1SERPINE1
SCHEMBL2838174 0.83 L3MBTL1 (0.52) KMT2AGAAL3MBTL1MEN1SMN1; SMN2
SCHEMBL2838173 0.83 KMT2A (0.49) KMT2AGAAL3MBTL1TDP1LMNA
SCHEMBL2835587 0.81 KMT2A (0.47) KMT2AL3MBTL1ATMTDP1SLC6A2
SCHEMBL2831997 0.78 KMT2A (0.54) KMT2AL3MBTL1ATMTDP1SLC6A3
SCHEMBL2831397 0.77 KMT2A (0.54) KMT2AGAALMNAMEN1ESR1
SCHEMBL2835178 0.76 KMT2A (0.60) KMT2ALMNAMEN1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 KMT2A 1023/4885GAA 990/4885L3MBTL1 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.